David Enloe, Jr. President and Chief Executive Officer
David Enloe brings over two decades of executive leadership experience in biotechnology, clinical drug development, and GMP manufacturing. Most recently, he served as president and chief executive officer of Ajinomoto Bio-Pharma Services, a global, fully integrated CDMO.
Prior to joining Ajinomoto, Enloe served as head of Lonza’s Viral Therapeutics business unit, which was the result of Lonza’s acquisition of Vivante GMP Solutions, a gene therapy CDMO that he founded in June 2009 and where he served as president and CEO until its sale to Lonza AG. Under Enloe’s leadership, the business experienced rapid expansion, with revenues increasing 500% over a three-year period.
Preceding Vivante, Enloe spent 14 years with biotech company, Introgen Therapeutics, joining as its first employee in 1995 and serving as senior vice president and COO before being named president and CEO. Enloe served an integral role in taking the company through a successful IPO in 2020, as well as several other significant financial transactions. In addition, Mr. Enloe oversaw multiple large corporate and academic collaborations, as well as the filing of license applications with both the FDA and European regulatory authorities for Introgen’s lead product.
Enloe received a Bachelor of Business Administration, Accounting, from the University of Texas at Austin. He is a Certified Public Accountant and started his career in public accounting with Arthur Andersen & Co.